What is HealthQuad's investment strategy?
HealthQuad is covered in Rupeia's venture capital research universe. The current public record describes the strategy as Early growth healthcare venture capital, with a sector focus of Healthtech, medtech, healthcare delivery, bio. The profile should be read with the linked source trail and Typical route: Category I AIF context.
What portfolio evidence is available for HealthQuad?
The profile displays only company or asset names attributable to HealthQuad in the reviewed public sources: LifeSigns, Qure.ai, Cureskin, Redcliffe Labs, Wysa, ekincare, RED.Health, HealthifyMe, BeatO, CarePal, Beta Drugs, GoApptiv. It does not represent a complete current portfolio unless the manager has published one.
What is known about HealthQuad's performance or track record?
The manager's portfolio identifies active holdings across diagnostics, AI-enabled clinical tools, chronic care, emergency response and healthcare distribution. Public reporting confirms a 2024 exit from AINU and reported a 4x return on that investment; this is a deal-specific outcome, not a fund-level return. These signals are not a substitute for fund- and vintage-specific net performance, realised distributions and audited or administrator-supported reporting.
What are HealthQuad's fund size, fees and minimum investment?
Public fund size: Fund III: ₹1,700 crore target and ₹550 crore first close reported in June 2026. Fund II closed at $162 million in 2022. Fund I, Fund II and Fund III are separate vehicles. Public terms or access information: Early-growth healthcare venture capital. Public materials describe investment in healthtech, medtech, novel healthcare delivery and bio/pharmtech; fees, carry, investment periods and cheque sizes are not publicly disclosed. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.
Who is on HealthQuad's investment team?
The current source record names Amit Varma (Co-Founder and IC Member); Abrar Mir (Co-Founder and IC Member); Sunil Thakur (Co-Founder and IC Member); Rahul Agarwal (Partner and IC Member); Charles-Antoine Janssen (Managing Partner and CIO). Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.
What risks should be reviewed before investing with HealthQuad?
Review stage concentration, follow-on reserves, company failure rates, dilution, exit timing and the gap between paper valuations and realised distributions. The current open diligence point is: Fund III final close, fee terms, cheque sizes, and vehicle-level realised return data are not publicly disclosed. Fund I, Fund II and Fund III have different legal Category I/II registrations; the profile represents the manager's healthcare venture strategy, not a substitute for a specific PPM.
What is the latest public update on HealthQuad?
2026-06-19: HealthQuad announced an investment in LifeSigns in May 2026, described as Fund III's first investment. June 2026 reporting stated that Fund III had raised ₹550 crore toward a ₹1,700 crore target.